Published online before print January 10, 2002, doi: 10.1161/hh0302.104724
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2002 American Heart Association, Inc.
Integrative Physiology |
Regression of Atherosclerosis in Monkeys Reduces Vascular Superoxide Levels
From the Department of Internal Medicine, University of Iowa College of Medicine and VA Medical Center, Iowa City, Iowa.
Correspondence to Francis J. Miller, Jr, MD, Dept of Internal Medicine, University of Iowa Hospitals, Iowa City, IA 52242. E-mail francis-miller{at}uiowa.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Superoxide (O2·-) in arteries may contribute to atherosclerosis in part by inactivation of nitric oxide. We hypothesized that regression of atherosclerosis in nonhuman primates is associated with a decrease in vascular NAD(P)H oxidase, decreased O2·- levels, and improved endothelium-dependent relaxation. Cynomolgus monkeys (n=28) were fed an atherogenic diet for 47±10 (mean±SE) months. In carotid arteries (containing advanced lesions), femoral arteries (moderate lesions), and saphena arteries (minimal lesions), we examined O2·- levels and vasomotor function. Compared with vessels from normal monkeys (n=8), O2·- levels (measured by lucigenin-enhanced chemiluminescence) were 3.3-fold higher in carotid, 1.7-fold higher in femoral, and not different in saphena arteries from atherosclerotic monkeys. Dihydroethidium staining also demonstrated increased O2·- levels throughout the vessel wall in femoral and carotid arteries from atherosclerotic monkeys. Components of the NAD(P)H oxidase (p22phox and p47phox) were increased in atherosclerotic arteries, and immunohistochemistry demonstrated colocalization primarily to areas of macrophage infiltration. Relaxation to acetylcholine was impaired in carotid and femoral, but not saphena, arteries from atherosclerotic monkeys. After 8 months of regression diet (n=9), serum cholesterol decreased to normal, and O2·- levels (basal and NAD(P)H-stimulated), as well as expression of NAD(P)H oxidase, returned toward normal. Relaxation to acetylcholine improved in femoral arteries, but not in the more diseased carotid arteries. We conclude that, in a primate model of moderately severe atherosclerosis and regression of atherosclerosis, changes in endothelial function are inversely related to O2·- and NAD(P)H oxidase levels. Reduction in vascular O2·- during regression of atherosclerosis may contribute to improvement in vasomotor function.
Key Words: oxidative stress • vascular reactivity • blood vessels • macrophages • endothelium
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Vascular levels of reactive oxygen species increase during hypercholesterolemia and may contribute to the pathophysiology of atherosclerosis. For example, reaction with superoxide (O2·-) reduces the bioavailability of nitric oxide (NO), which impairs vasomotor function,1 and increases platelet aggregation and monocyte adhesion. Superoxide can also activate matrix metalloproteinases and produce apoptosis, which may contribute to instability of atherosclerotic lesions.2–4
Reduction of cholesterol levels in patients with established coronary artery disease markedly reduces the risk of major coronary events.5–8 Improvement in vasomotor function and clinical benefits, however, occur much more rapidly than structural improvement during regression, possibly through an increase in the bioavailability of NO.8,9 This observation is compatible with the hypothesis that regression of atherosclerosis is associated with reduction of vascular reactive oxygen species (ROS) levels.
Macrophages, smooth muscle, fibroblasts, and endothelium all are potential sources of O2·- in blood vessels.2,10–12 Reduction of endothelial O2·- by a gene transfer approach is not sufficient to restore NO-mediated relaxation in atherosclerotic aorta,10 suggesting that O2·- generation by other cell types may contribute importantly to inactivation of NO. The effect of regression of atherosclerosis on O2·- levels in different cellular components of the vessel wall has not been studied.
The primary goal of this study was to examine effects of regression of atherosclerosis on vascular O2·- levels. We used a nonhuman primate model of regression to examine O2·- levels and endothelium-dependent relaxation in arteries that vary in the severity of atherosclerosis (carotid, severe lesion; femoral, moderate lesion; saphena, minimal lesion). We tested the hypothesis that regression of chronic atherosclerosis would decrease levels of O2·- in diseased blood vessels and result in improvement of vascular function. We also hypothesized that during regression, reduction of vascular O2·- levels would be associated with a decrease in NAD(P)H oxidase activity, a major source of O2·- in vascular cells.12
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Preparation
The Institutional Care and Use Committee of the University of Iowa approved experiments in this study. Adult male Cynomolgus monkeys were obtained from Biomedical Research Foundation (Houston, Tex) and fed a normal diet (Purina monkey chow, Ralston Purina; n=8) or an atherogenic diet (cholesterol 1 mg/calorie; fat, 43% of total calories, n=29). After 45±1 months (mean±SE) on an atherogenic diet, segments of common carotid, femoral, and saphena arteries were harvested (atherosclerotic) from anesthetized monkeys (ketamine, 20 mg/kg IM; sodium pentobarbital, 20 mg/kg IV and supplemented when needed). Some monkeys were allowed to recover and placed on a normal diet (regression group, n=9). After 8 months of regression, monkeys were sedated (ketamine, 20 mg/kg IM), euthanized with an intravenous injection sodium pentobarbital (200 mg/kg), and contralateral segments of common carotid, femoral, and saphena arteries were removed. Loosely adhering adventitia was removed, vessels were cut into 3- to 4-mm segments and kept in Kreb’s buffer (4°C) until their use. Kreb’s buffer contained (in mmol/L) NaCl 118, KCl 4.7, CaCl 2.5, MgSO4 1.2, NaHCO3 23, KH2PO4 1.2, and D-glucose 11. Blood samples were taken at the termination of the study for the measurement of plasma lipids.
Measurement of Isometric Tension
Vascular rings were mounted on stainless steel hooks and placed in an organ chamber bath that contained warm (37°C), aerated (95% O2, 5% CO2) Kreb’s buffer. Preliminary experiments were used to determine optimal resting tension of carotid, femoral, and saphena arteries (3 g, for all vessels), which was used in subsequent experiments. Rings were contracted twice with 60 mmol/L KCl and rinsed 3 times after each contraction. As an index of endothelium-dependent vasodilation, cumulative concentration-response curves were generated for acetylcholine (10-9 to 10-5 mol/L) after precontraction with PGF2
(60% to 85% of maximum contraction with KCl). Levels of precontraction with PGF2 were similar between groups. Relaxation to sodium nitroprusside (10-5 mol/L) was examined in each vessel segment as a measure of endothelium-independent relaxation.
Measurement of Superoxide
Lucigenin-enhanced chemiluminescence was used to assess levels of O2·- in vascular rings.10,13 Samples were added to polypropylene cuvettes containing phosphate-buffered saline (PBS; NaCl 137 mmol/L; KCl 2.7 mmol/L; Na2HPO4 4.3 mmol/L; KH2PO4 1.5 mmol/L) and lucigenin (0.005 mmol/L), and chemiluminescence was measured using a luminometer (Zylux, FB12). After dark adaptation, basal chemiluminescence was measured for 5 minutes. Cumulative concentrations of NADH (0.2 and 1 mmol/L) or NADPH (0.2 and 1 mmol/L) were added and luminescence was measured for an additional 5 minutes for each concentration. In some samples, the flavin inhibitor diphenyleneiodonium chloride (DPI, 0.1 mmol/L) was added after the final dose of NAD(P)H, and a 5-minute measurement of chemiluminescence performed. Other samples were pretreated with the O2·- scavenger Tiron (10 mmol/L), or inhibitors of nitric oxide synthase (NG-nitro-L-arginine, L-NNA, 0.01 mmol/L) or xanthine oxidase (oxypurinol, 0.1 mmol/L) for 30 minutes prior to chemiluminescence measurements as described. Relative light unit values were normalized to the surface area of the vessel.
Dihydroethidium (DHE), an oxidative fluorescent dye, was used to localize O2·- in vessel segments in situ as previously described.10 Briefly, fresh, unfixed vessel segments were frozen in OCT compound until the detection of O2·-. Transverse sections (30 µm thick) were cut in a cryostat and placed on glass slides. Samples were then incubated at room temperature for 30 minutes with DHE (0.002 mmol/L) and protected from light. Images were obtained using a Bio-Rad MRC-1024 laser (krypton/argon) scanning confocal microscope. The fluorescence excitation/emission spectrum for ethidium bromide was used during the imaging process (488 and 610 nm, respectively). Fluorescence was detected with a 585-nm long-pass filter.
Immunohistochemistry
Immunohistochemistry for macrophages and subunits of the NAD(P)H oxidase (p22phox and p47phox) were examined using a previously described protocol.14 Briefly, sections of fresh-frozen blood vessels (8 µm thick) were placed on slides and air dried overnight (-20°C). Normal horse serum (1 hour) was used as a blocking agent. Primary antibodies against p22phox (monoclonal antibody 44.1, obtained from Dr A.J. Jesaitis, Dept of Microbiology, Montana State University), p47phox (Santa Cruz Biotechnology), or macrophages (HAM 56) were added to the tissue sample for 1 hour and then washed 3 times with PBS. The secondary antibody, biotinylated anti-mouse (p22phox and HAM 56) or anti-goat (p47phox), was added to the tissue for 30 minutes, washed, and strep-avidin was added for another 30 minutes. Vector Blue was used as a chromogenic substrate, and the tissue sections were fixed in paraformaldehyde, washed, and counterstained with nuclear fast red. Tissue sections not treated with a primary antibody showed no staining after treatment with the secondary antibody.
Data Analysis
Data were tested for normality and homogeneity of variance. If either of these assumptions were not satisfied, the data were log transformed and tested again. Data from the vascular reactivity experiments were analyzed using a 2-way ANOVA. All other data were analyzed using 1-way ANOVA followed by the Dunnett’s method for multiple comparisons. All data are presented as mean±SE. Differences were considered to be significant when P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Physiological Parameters
The atherogenic diet produced increases in plasma low-density lipoproteins from 32±8 to 326±24 mg/dL and total cholesterol from 90±7 in normals to 373±23 mg/dL in atherosclerotic monkeys. Eight months of regression (normal) diet reduced levels of low-density lipoproteins to 24±3 mg/dL and total cholesterol to 64±4 mg/dL. There were no significant differences in body weight, plasma triglyceride levels, or hematocrit (data not shown) between normal, atherosclerotic, and regression groups of monkeys.
Morphometric Data
We chose to examine common carotid, femoral, and saphena arteries because we anticipated that the atherogenic diet would produce different severity of disease in these vessels. In normal monkeys, there was little or no neointimal formation in carotid, femoral, and saphena arteries. In atherosclerotic monkeys, intimal area and the ratio of intima to media were increased in the carotid and femoral arteries, but not in the saphena artery (Figure 1). The medial area of carotid, femoral, and saphena arteries was not altered by the atherogenic diet (data not shown). There was no significant decrease in the intimal area or intima to media ratio of carotid, femoral, or saphena arteries after 8 months of the regression diet (Figure 1).
|
Vasomotor Responses
Maximal contractions of femoral and saphena arteries to KCl were not altered in atherosclerotic or regression monkeys, but contraction of carotid arteries was impaired (5.1±0.3 g for normal versus 2.5±0.3 g for atherosclerotic, P<0.05). Contraction of carotid arteries to KCl did not improve after regression.
After precontraction to similar levels in all groups, relaxation of carotid and femoral arteries to acetylcholine was significantly attenuated in monkeys from the atherosclerotic group when compared with normal (Figure 2). There was no significant impairment of relaxation to acetylcholine in saphena arteries. After 8 months on a regression diet, relaxation of carotid arteries to acetylcholine was not improved (Figure 2). In contrast, after regression in femoral arteries, relaxation to acetylcholine was normal. Maximal relaxation of carotid, femoral, and saphena arteries to sodium nitroprusside did not differ between groups.
|
P<0.01 regression vs atherosclerotic.
Superoxide Levels
Basal levels of O2·-, as detected with lucigenin-enhanced chemiluminescence, were similar in carotid, femoral, and saphena arteries harvested from normal animals. Levels of O2·- were elevated in femoral and carotid arteries of atherosclerotic monkeys, compared with normals (Figure 3A). Despite prolonged hypercholesterolemia, the saphena artery did not develop significant atherosclerotic lesions (Figure 1) or increase in basal O2·- levels (Figure 3A). After 8 months of normocholesterolemia, basal levels of O2·- decreased in carotid, femoral, and saphena arteries from regression monkeys to near normal levels (Figure 3A).
|
Dihydroethidium staining of vessel sections suggested that O2·- levels were increased throughout atherosclerotic arteries (especially in the neointima) when compared with those of normal animals (Figure 3B). Consistent with chemiluminescence data, DHE staining for O2·- decreased in blood vessels from monkeys in the regression group (Figure 3B). With regression, DHE fluorescence appeared to decrease most in intimal cells, but also in cells in the media and adventitia. The elastic laminae and calcified areas of the intima demonstrated autofluorescent properties (Figure 3B, shown in yellow). Autofluorescence decreased in some regression vessels and may represent decreased calcification of lesion or breakdown of the elastic laminae.
NAD(P)H-Stimulated Production of O2·-
The flavin inhibitor DPI and the radical scavenger Tiron markedly inhibited O2·- in femoral arteries from atherosclerotic monkeys, whereas inhibition of nitric oxide synthase (L-NNA) and xanthine oxidase (oxypurinol) had no effect (Figure 4), suggesting an NAD(P)H oxidase as a source of O2·-.
|
Addition of NADH to vascular segments increased O2·- to similar levels in carotid, femoral, and saphena arteries from normal animals (Figure 5A). NADH-stimulated chemiluminescence was increased in the atherosclerotic group and returned to normal levels in the regression group in all vessels examined (Figure 5A). NADPH stimulation produced similar increases in levels of O2·- of normal carotid, femoral, and saphena arteries (Figure 5B). In atherosclerotic vessels, in contrast to NADH stimulation, NADPH-stimulated O2·- levels differed in arteries with different amounts of lesion (Figure 5B). For example, the carotid artery, with the most severe atherosclerosis, had the greatest level of O2·- after NADPH treatment, and the saphena, the artery with the least disease, had the lowest levels of O2·- after NADPH. The flavoenzyme inhibitor DPI reduced NADPH-stimulated O2·- levels in atherosclerotic vessels by approximately 70%. After regression, levels of NADPH-stimulated O2·- were similar to those of normal vessels (Figure 5B).
|
Expression of the NAD(P)H oxidase was examined by immunostaining for both the membrane-associated component p22phox and the cytosolic component p47phox. Staining for p22phox and p47phox were increased in carotid and femoral arteries with the greatest staining localized to areas that also stained for macrophages (Figure 6). There was a decrease in immunostaining for p22phox and p47phox in arteries from regression animals, again primarily associated with intimal areas that also stained positive for macrophages (Figure 6). Expression of p22phox and p47phox was also increased in the smooth muscle cells of the medial layer of femoral arteries from atherosclerotic monkeys and decreased toward normal in arteries from regression animals (Figure 7). Similar changes in expression of p22phox and p47phox were seen in carotid arteries (not shown).
|
|
Macrophage Infiltration
There were few, if any, macrophages detected by immunohistochemistry in normal arteries. In contrast, many macrophages were found in the intima and adventitia of atherosclerotic femoral arteries (Figure 6). After regression, there were fewer macrophages in the intima and persistence of many macrophages in the adventitia of femoral arteries (Figure 6). Similar results were obtained in carotid arteries. Macrophage infiltration was limited to the adventitia in saphena arteries, in which intimal lesions were not observed (data not shown).
Time Controls
Three atherosclerotic monkeys were maintained on a high cholesterol diet after removal of the carotid, femoral, and saphena arteries. Eight months later the contralateral arteries were studied as a time control for the regression animals. In these vessels, intimal lesion size in the femoral and carotid vessels did not change noticeably with the additional 8 months of atherosclerotic diet. The saphena artery contained no intimal thickening. In contrast to regression monkeys, relaxation of carotid and femoral arteries to acetylcholine (10-5 mol/L) tended to be more impaired in vessels from the time control group compared with atherosclerotic vessels (28±18% and 51±22% in the carotid and femoral time controls, respectively). Dihydroethidium staining for O2·- and immunostaining for macrophages and p47phox and p22phox were similar in the time control vessels compared with atherosclerotic vessels.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The major findings in this model of prolonged atherosclerosis followed by a short duration of regression in primates are as follows. (1) In atherosclerotic animals, lesion severity is related to O2·- levels and magnitude of impaired relaxation to acetylcholine. (2) After a relatively short period of reduction of cholesterol, O2·- levels decreased in atherosclerotic femoral and carotid artery, but endothelium-mediated relaxation improved only in the less diseased femoral artery. (3) After regression of atherosclerosis, decreases in O2·- levels are associated with decreases in NAD(P)H oxidase activity and decreased expression of oxidase subunits p22phox and p47phox. (4) Reduction in O2·- levels and oxidase expression in the vessel wall following regression of atherosclerosis is associated with reduction in intimal macrophages, but not lesion size.
In animal models, vascular O2·- levels are increased after a short period of hypercholesterolemia and associated with abnormal nitric oxide–mediated relaxation.1 Vasomotor function and O2·- levels are restored to normal after a short period of normocholesterolemia.15 Although this observation suggests that regression of atherosclerosis is associated with decreased vascular ROS, lesions in short-term models of hypercholesterolemia are not representative of lesions found in humans. For example, in hypercholesterolemic rabbits, the majority of aorta examined contained no macrophages,15 an important potential source of O2·-. The current study used a primate model of chronic hypercholesterolemia in which moderate to severe lesions developed in the femoral and carotid arteries.
The saphena artery did not develop significant intimal thickening or impaired endothelium-dependent relaxation, despite more than 4 years of hypercholesterolemia. It is not clear why saphena arteries are protected during hypercholesterolemia. It is of interest that the absence of atherosclerotic lesions in saphena arteries was associated with normal relaxation to acetylcholine because others have found impairment of endothelium-dependent relaxation during hypercholesterolemia without atherosclerotic lesions.15–17 We did not observe a significant increase in basal levels of O2·- in the saphena, which could contribute to preservation of normal endothelium-dependent relaxation.
In contrast to minimal atherosclerosis in saphena arteries, moderately severe atherosclerosis was observed in carotid arteries. Despite reduction in O2·- levels, relaxation of carotid artery to acetylcholine did not improve after reduction of plasma cholesterol. Thus, reduction in O2·- levels is not sufficient to improve endothelium-dependent relaxation in the presence of moderately severe atherosclerosis. However, O2·- levels in carotid arteries from the regression group remained higher than O2·- levels in carotid arteries from normal monkeys (Figure 3A). This persistent increase in O2·- may contribute to impaired relaxation of carotid arteries after regression. Our previous studies of regression of atherosclerosis in monkeys demonstrated improved endothelial function in carotid arteries.18,19 Differences in the duration of atherogenic diet, duration of regression, and branch of the carotid studied may account for differences in results between these studies and the current study.
Hyperhomocysteinemia may produce vascular dysfunction through increased levels of O2·-.20 In addition to hypercholesterolemia, the atherogenic diet used in this study also produces moderate homocysteinemia.21 It is unlikely, however, that changes in homocysteine contributed importantly to vascular dysfunction and increase in O2·- associated with atherosclerosis in this study because reduction of homocysteine alone does not restore endothelial function.21 We cannot completely exclude, however, the possibility that reduction of homocysteine during regression contributed to the reduction of O2·- levels and improvement in vascular function.
The conclusion that regression of atherosclerosis is associated with reduction in vascular NAD(P)H oxidase activity is supported by the finding of decreased O2·- generation in response to NADPH and NADH, and by decreased expression of the oxidase subunits p22phox and p47phox, in vessels after regression. Because inflammatory cells are present in atherosclerotic arteries, however, it is difficult to distinguish whether changes in NAD(P)H oxidase activity reflect changes in macrophage number or oxidase activity in vascular cells. Reduction in levels of O2·- and oxidase subunit expression is associated with a decrease in the number of intimal macrophages. Two findings, however, suggest that regression of atherosclerosis also decreases vascular NAD(P)H oxidase function. First, fluorescence of DHE and expression of p22phox and p47phox decrease throughout the vessel wall after regression, suggesting a reduction in NAD(P)H activity in nonphagocytic cells. Second, NADH-stimulated O2·- levels increase to similar levels in the 3 types of vessels examined, despite different degrees of lesion size and macrophage content, and return to normal with regression of atherosclerosis. If NADH-stimulated O2·- in atherosclerotic vessels were derived only from macrophages, levels of O2·- would correlate with lesion size. Furthermore, both NADH and NADPH are used as substrate for the vascular NAD(P)H oxidase,22 whereas the phagocyte NADPH oxidase uses NADPH almost exclusively.23 These observations suggest that a reduction in both phagocyte and nonphagocyte (vascular cell) NAD(P)H oxidase function contribute to reduction of levels of O2·- during regression of atherosclerosis.
It is controversial whether addition of NADH and NADPH to intact vessels accurately reflects NAD(P)H oxidase activity. Others have demonstrated convincingly that addition of NADH or NADPH to intact vessel segments produces increases in levels of O2·-.24–26 In intact vessel segments, addition of NADH or NADPH increases levels of O2·- detected by electron paramagnetic resonance spectroscopy, HE staining, or a sensitive bioassay that measures the ability of O2·- to scavenge NO.24,25 NAD(P)H oxidase activity measured in intact vessel segments correlates with measurements made in vessel homogenate.24,27 In addition, our conclusions, based on the chemiluminescence data, are supported by the findings of increased immunostaining of oxidase components p22phox and p47phox. In human atherosclerotic coronary arteries, expression of p22phox was increased throughout the vessel wall, especially within the intima.28 Our results are consistent with these findings.
In clinical trials, reduction of plasma cholesterol in patients with coronary atherosclerosis reduces major coronary events, including death. Angiographic studies have shown that reduction in clinical events occurs despite only small effects on lumen diameter.5–8,29 Therefore, the clinical benefit of regression may be due to stabilization of lesions, not to effects on lumen diameter. Our finding of reduction in vascular oxidative stress with regression is consistent with this hypothesis.
This study provides evidence for an association of changes in several parameters, without proof of causal relationship, and is therefore inherently limited. Two experimental approaches, however, strengthen the conclusions. First, we studied changes in 3 types of arteries that were exposed to the same level of hypercholesterolemia (and hyperhomocysteinemia), but demonstrated profoundly different severity and consequences of atherosclerosis. This approach allowed us to discriminate between changes produced by atherosclerosis versus hypercholesterolemia. Second, we used an intervention (regression of atherosclerosis) that is timely and of interest per se, and also may be of value in discriminating between associations and causal relationships. Nevertheless, it is important to acknowledge that the changes that we have observed are associations and may or may not be causally related.
In summary, our findings suggest that O2·- levels are increased and endothelium-dependent relaxation is impaired in large arteries of monkeys with moderate atherosclerosis, and that these effects are due at least in part to increased expression and activation of NAD(P)H oxidase within the vessel wall. Moreover, O2·- levels and vascular function in these arteries return toward normal within a few months of regression of atherosclerosis. Increases in expression of the p47phox and p22phox subunits of the NADPH oxidase largely colocalize with macrophages in diseased vessels and disappear from the intima after regression. NAD(P)H oxidase activity of intimal phagocytes appears to be important in vascular dysfunction that occurs with atherosclerosis. Furthermore, improvement of vascular function is associated with reduction of macrophages and NAD(P)H oxidase components in atherosclerotic vessels.
|
Acknowledgments |
|---|
This work was supported by grants from the NIH (HL-62984, NS-24621, HL-16066, HL-14388, HL-03669, and HL-37386) and the VA Medical Center. The authors would like to thank Drs Frank Faraci and Steven Lentz for their critical review of this manuscript. In addition, we would like to thank Robert Brooks II and Pamela Tompkins for their expert technical assistance.
Received August 9, 2001; revision received December 21, 2001; accepted December 21, 2001.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993; 91: 2546–2551.[Medline] [Order article via Infotrieve]
2. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest. 1996; 98: 2572–2579.[Medline] [Order article via Infotrieve]
3. Griendling KK, Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. J Lab Clin Med. 1998; 132: 9–15.[CrossRef][Medline] [Order article via Infotrieve]
4.
Li P-F, Dietz R, von Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation. 1997; 96: 3602–3609.
5. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Eng J Med. 1990; 323: 1289–1298.[Abstract]
6. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients: Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet. 1994; 344: 1182–1186.[CrossRef][Medline] [Order article via Infotrieve]
7.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335: 1001–1009.
8.
Levine GN, Keaney JFJ, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med. 1995; 332: 512–521.
9.
Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation. 1994; 89: 1810–1818.
10.
Miller FJJ, Gutterman DD, Rios CD, Heistad DD, Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res. 1998; 82: 1298–1305.
11.
Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Nat Acad Sci U S A. 1997; 94: 14483–14488.
12. Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol. 1994; 266: H2568–72.[Medline] [Order article via Infotrieve]
13.
Li Y, Zhu H, Kuppusamy P, Roubaud V, Zweier JL, Trush MA. Validation of lucigenin (Bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J Biol Chem. 1998; 273: 2015–2023.
14.
Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation. 1998; 98: 800–807.
15.
Ohara Y, Peterson TE, Sayegh HS, Subramanian RR, Wilcox JN, Harrison DG. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation. 1995; 92: 898–903.
16.
Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation. 1997; 95: 2617–2622.
17.
Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation. 1990; 81: 1586–1593.
18. Faraci FM, Orgren K, Heistad DD. Impaired relaxation of the carotid artery during activation of ATP-sensitive potassium channels in atherosclerotic monkeys. Stroke. 1994; 25: 178–182.[Abstract]
19.
Sobey CG, Faraci FM, Piegors DJ, Heistad DD. Effect of short-term regression of atherosclerosis on reactivity of carotid and retinal arteries. Stroke. 1996; 27: 927–933.
20. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 2000; 106: 483–491.[Medline] [Order article via Infotrieve]
21.
Lentz SR, Malinow MR, Piegors DJ, Bhopatkar-Teredesai M, Faraci FM, Heistad DD. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol. 1997; 17: 2930–2934.
22. Sorescu D, Somers M, Lassegue B, Grant S, Harrison DG, Griendling KK. Electron spin resonance characterization of the NAD(P)H oxidase in vascular smooth muscle cells. Free Radic Biol Med. 2001; 30: 603–612.[CrossRef][Medline] [Order article via Infotrieve]
23. Griendling KK, Ushio-Fukai M. NADH/NADPH oxidase and vascular function. Trends in Cardiovasc Med. 1997; 7: 301–307.[CrossRef]
24.
Souza HP, Laurindo FRM, Ziegelstein RC, Berlowitz CO, Zweier JL. Vascular NAD(P)H oxidase is distinct from the phagocytic enzyme and modulates vascular reactivity control. Am J Physiol Heart Circ Physiol. 2001; 280: H658–H667.
25.
Mulsch A, Oelze M, Kloss S, Mollnau H, Topfer A, molenski A, alter U, Stasch JP, Warnholtz A, Hink U, Meinertz T, Munzel T. Effects of in vitro nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation. 2001; 103: 2188–2194.
26. Sorescu D, Somers MJ, Lassegue B, Grant S, Harrison DG. Electron spin resonance characterization of the NAD(P)H oxidase in vascular smooth muscle cells. Free Radic Biol Med. 2001; 30: 603–612.[CrossRef][Medline] [Order article via Infotrieve]
27. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000; 86: e85–e90.[Medline] [Order article via Infotrieve]
28.
Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, Yokoyama M. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation. 1999; 100: 1494–1498.
29. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Ann Rev Med. 1993; 44: 365–376.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  J. D. Miller, R. M. Weiss, K. M. Serrano, R. M. Brooks II, C. J. Berry, K. Zimmerman, S. G. Young, and D. D. Heistad Lowering Plasma Cholesterol Levels Halts Progression of Aortic Valve Disease in Mice Circulation, May 26, 2009; 119(20): 2693 - 2701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tsimikas, M. Aikawa, F. J. Miller Jr, E. R. Miller, M. Torzewski, S. R. Lentz, C. Bergmark, D. D. Heistad, P. Libby, and J. L. Witztum Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering: A Potential Biomarker of Early Atherosclerosis Regression Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 175 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ohashi, M. S. Runge, F. M. Faraci, and D. D. Heistad MnSOD Deficiency Increases Endothelial Dysfunction in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2331 - 2336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gorenne, M. Kavurma, S. Scott, and M. Bennett Vascular smooth muscle cell senescence in atherosclerosis Cardiovasc Res, October 1, 2006; 72(1): 9 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Matthews, I. Gorenne, S. Scott, N. Figg, P. Kirkpatrick, A. Ritchie, M. Goddard, and M. Bennett Vascular Smooth Muscle Cells Undergo Telomere-Based Senescence in Human Atherosclerosis: Effects of Telomerase and Oxidative Stress Circ. Res., July 21, 2006; 99(2): 156 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Heistad Oxidative Stress and Vascular Disease: 2005 Duff Lecture Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 689 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Symons, J. C. Rutledge, U. Simonsen, and R. A. Pattathu Vascular dysfunction produced by hyperhomocysteinemia is more severe in the presence of low folate Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H181 - H191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Iida, Y. Chu, J. Francis, R. M. Weiss, C. A. Gunnett, F. M. Faraci, and D. D. Heistad Gene transfer of extracellular superoxide dismutase improves endothelial function in rats with heart failure Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H525 - H532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Li and A. M Shah Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1014 - R1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sato, T. Komaru, H. Shioiri, S. Takeda, K. Takahashi, H. Kanatsuka, M. Nakayama, and K. Shirato Hypercholesterolemia Impairs Transduction of Vasodilator Signals Derived From Ischemic Myocardium: Myocardium-Microvessel Cross-Talk Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 2034 - 2039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stocker and J. F. Keaney Jr. Role of Oxidative Modifications in Atherosclerosis Physiol Rev, October 1, 2004; 84(4): 1381 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S Conklin, W. Fu, P. H Lin, A. B Lumsden, Q. Yao, and C. Chen HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries Cardiovasc Res, July 1, 2004; 63(1): 168 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kawashima and M. Yokoyama Dysfunction of Endothelial Nitric Oxide Synthase and Atherosclerosis Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 998 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Munzel, R. Feil, A. Mulsch, S. M. Lohmann, F. Hofmann, and U. Walter Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase Circulation, November 4, 2003; 108(18): 2172 - 2183. [Full Text] [PDF]
|
|
|
|
|
|
B. Lassegue and R. E. Clempus Vascular NAD(P)H oxidases: specific features, expression, and regulation Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2003; 285(2): R277 - R297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mollnau, E. Schulz, A. Daiber, S. Baldus, M. Oelze, M. August, M. Wendt, U. Walter, C. Geiger, R. Agrawal, et al. Nebivolol Prevents Vascular NOS III Uncoupling in Experimental Hyperlipidemia and Inhibits NADPH Oxidase Activity in Inflammatory Cells Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 615 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhang, T. W. Hein, W. Wang, and L. Kuo Divergent Roles of Angiotensin II AT1 and AT2 Receptors in Modulating Coronary Microvascular Function Circ. Res., February 21, 2003; 92(3): 322 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dayal, K. L. Brown, C. J. Weydert, L. W. Oberley, E. Arning, T. Bottiglieri, F. M. Faraci, and S. R. Lentz Deficiency of Glutathione Peroxidase-1 Sensitizes Hyperhomocysteinemic Mice to Endothelial Dysfunction Arterioscler Thromb Vasc Biol, December 1, 2002; 22(12): 1996 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Bucciarelli, T. Wendt, W. Qu, Y. Lu, E. Lalla, L. L. Rong, M. T. Goova, B. Moser, T. Kislinger, D. C. Lee, et al. RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E-Null Mice Circulation, November 26, 2002; 106(22): 2827 - 2835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Lentz, F. J. Miller Jr, D. J. Piegors, R. A. Erger, J. A. Fernandez, J. H. Griffin, and D. D. Heistad Anticoagulant Responses to Thrombin Are Enhanced During Regression of Atherosclerosis in Monkeys Circulation, August 13, 2002; 106(7): 842 - 846. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||